Corrigendum to "Social consequences and genetics for the child with overweight and obesity: An obesity medicine association (OMA) clinical practice statement 2022" [Obes. Pillars 3 (2022) 100032] [0.03%]
对“肥胖和超重儿童的社会后果和遗传学：肥胖医学协会（OMA）2022年临床实践声明”一文的勘误[Obes. Pillars 3 (2022) 100032]
Suzanne Cuda,Marisa Censani,Roohi Kharofa et al.
Suzanne Cuda et al.
[This corrects the article DOI: 10.1016/j.obpill.2022.100032.]. © 2022 Published by Elsevier Inc. on behalf of Obesity Medicine Association.
Published Erratum
Obesity pillars. 2022 Sep 26:4:100037. DOI:10.1016/j.obpill.2022.100037 2022
A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center [0.03%]
新冠肺炎疫情期间三级体重管理中心抗肥胖药物减重效果的比较研究
Alan De la Rosa,Wissam Ghusn,Daniel Sacoto et al.
Alan De la Rosa et al.
Background: /Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective for weight loss. However, weight loss outcomes with AOM during the COVID-19 pan...
Corrigendum to "Nutritional and activity recommendations for the child with normal weight, overweight, and obesity with consideration of food insecurity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022" [Obesity Pillars 2 (2022) 100012] [0.03%]
关于“考虑食物不安全因素的正常体重、超重和肥胖儿童的营养和活动建议：肥胖医学协会(OMA)临床实践声明2022”的勘误声明
Nancy T Browne,Suzanne E Cuda
Nancy T Browne
[This corrects the article DOI: 10.1016/j.obpill.2022.100012.]. © 2022 The Author(s).
Published Erratum
Obesity pillars. 2022 Sep 24:4:100036. DOI:10.1016/j.obpill.2022.100036 2022
Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 [0.03%]
肥胖儿童的药物诱导体重增加和先进疗法：肥胖医学协会(OMA)临床实践声明2022年
Suzanne Cuda,Marisa Censani,Roohi Kharofa et al.
Suzanne Cuda et al.
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details medication-induced weight gain and advanced therapies for the child with overweight or obesity. ...
Wissam Ghusn,Maria Daniela Hurtado,Andres Acosta
Wissam Ghusn
Background: Chronic non-communicable diseases (CNCD) represent a major cause of morbidity and mortality. Type 2 diabetes mellitus (T2DM) is one of the most prevalent CNCD that is associated with a significant medical and ...
Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 [0.03%]
压力、精神疾病和肥胖症：肥胖医学协会（OMA）临床实践声明（CPS）2022年
Sandra M Christensen,Catherine Varney,Vivek Gupta et al.
Sandra M Christensen et al.
Background: Previous Obesity Medicine Association (OMA) Clinical Practice Statements (CPS) included topics such as behavior modification, motivational interviewing, and eating disorders, as well as the effect of concomita...
Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs) [0.03%]
肥胖专栏圆桌讨论：利用高效减肥药物实现过度体重减轻（他AOM）
Harold Edward Bays,Karli Burridge,Jesse Richards et al.
Harold Edward Bays et al.
Background: Historically, many anti-obesity medications (AOMs) were withdrawn from development and/or the market due to safety concerns. Another challenge was that, with some exceptions, most of these AOMs had limited wei...
Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 [0.03%]
人工智能与肥胖管理：肥胖医学协会（OMA）临床实践声明（CPS）2023年
Harold Edward Bays,Angela Fitch,Suzanne Cuda et al.
Harold Edward Bays et al.
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management of patients with obesity. ...
Obesity medicine as a subspecialty and United States certification - A review [0.03%]
肥胖病学作为亚专科和美国认证-综述文章
Angela Fitch,Deborah B Horn,Christopher D Still et al.
Angela Fitch et al.
Background: Certification of obesity medicine for physicians in the United States occurs mainly via the American Board of Obesity Medicine (ABOM). Obesity medicine is not recognized as a subspecialty by the American Board...
Clinical review: Guide to pharmacological management in pediatric obesity medicine [0.03%]
儿科肥胖医学药物管理指南临床综述
Valerie O&#x;Hara,Suzanne Cuda,Roohi Kharofa et al.
Valerie O&#x;Hara et al.
Introduction: Newer pharmacotherapy agents (anti-obesity medication [AOM]) are revolutionizing the management of children and adolescents with obesity. Previously, treatment based on intensive behavioral therapy involved ...